UFP Technologies, Inc. (UFPT): what the price assumes

In the published model solve dated 2026-Q2, anchored at $300.05, UFP Technologies, Inc. (UFPT) is priced for today's economics sustained for ~5.2 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-06-28.

Generated: 2026-08-30 · Exported: 2026-08-31 · Source: https://boothcheck.com/report/UFPT

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 6: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 9.5% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: within-range (limited comparison data)

Valuation X-Ray

Every valuation family lands below the price. The price therefore sits beyond what those standard frames encode.

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 8.8%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Bullet Takeaways

• UFP Technologies makes custom engineered components for medical-device makers, in markets like minimally invasive surgery, orthopedics, and wound care, and the business has shifted decisively toward medical, which reached $143.4 million of Q1 2026 sales, up 5.9%.
• The defining customer relationship is Intuitive Surgical: UFP extended and expanded its supply agreement through December 31, 2029, adding contracted-revenue visibility to the robotic-surgery franchise.
• The risk to weigh is concentration: the top ten customers were 68.8% of 2025 net sales, with Intuitive Surgical and Stryker the two largest, per the filing, so the franchise quality and the dependency are the same fact.

Bull Case

The earnings trajectory tells a clean story of a company that has remade itself into a medical-device supplier. Q1 2026 medical sales rose 5.9% to $143.4 million while non-medical revenue fell 15.0% to $10.8 million, so the medical mix is now the overwhelming majority of the business and growing while the legacy non-medical work fades. The 10-K lists the segments UFP serves, "minimally invasive surgery, infection control, orthopedics, interventional & surgical, surfaces & support, therapeutics, diagnostics, wound care, and biopharma", and describes products that "often are custom-made to its customers' specifications". Custom-engineered medical components designed into a device carry switching costs a commodity supplier never has: once UFP's part is specified into an approved medical device, replacing it means re-validation the customer would rather avoid.

The Intuitive Surgical relationship is the franchise's anchor and its clearest growth signal. In late February 2026 UFP extended and expanded its manufacturing supply agreement with Intuitive through December 31, 2029, a longer-term, higher-volume partnership that adds contracted-revenue visibility. Robotic surgery is one of the fastest-growing areas in medical devices, and being the designed-in component supplier to the category leader is a position that compounds with the customer's own volume growth. Q1 highlighted strength in robotic surgery, patient surfaces and support, and interventional and surgical segments, with capacity additions in the Dominican Republic coming in Q2.

The growth has been amplified by disciplined acquisition. In 2025 UFP acquired Universal Plastics & Engineering (UNIPEC) and Techno Plastics Industries (TPI) to add tight-tolerance film components and thermoplastic molding for the medical-device market, deepening the capabilities it can offer the same medical customers. Q1 2026 net income rose to $17.5 million on sales of $154.2 million, with GAAP EPS of $2.24. A company that is both growing the medical core organically and buying complementary capabilities, while keeping leverage modest, is the profile the price is paying a premium for.

Bear Case

The capital-allocation story has a concentration problem baked into it, and the filing states it without hedging. UFP's top ten customers represented approximately 68.8% of total net sales in 2025, up from 59.3% two years earlier, and two customers, "Intuitive Surgical SARL and Stryker", are the largest. That rising concentration is the flip side of the medical-device success: the same designed-in relationships that create switching costs also mean a large share of revenue sits with a handful of buyers. If Intuitive or Stryker re-sources a program, slows its own volume, or pushes hard on price at the next contract renewal, the impact on UFP is immediate and large. The expanded Intuitive agreement through 2029 is a genuine positive, but it also formalizes the dependency: the customer that most drives the growth is the customer the company can least afford to lose.

The price assumes that concentrated, premium franchise keeps compounding at a premium multiple, and the methods say the premium is real. The price sits well above the asset-value and earnings-power methods, which land at roughly a third to a half of it, because UFP earns a high return on a relatively small capital base and the market capitalizes that quality richly. The bet is that the medical mix, the Intuitive volumes, and the acquisition pipeline together sustain the growth that justifies paying several times book and a rich multiple of current earnings. If medical-device end markets slow or a key program is lost, the multiple compresses fast, because a premium paid for durable growth unwinds quickly when the durability is questioned.

The non-medical decline is a quieter signal worth watching. Non-medical revenue fell 15% in the quarter, and while management is deliberately deemphasizing it, a shrinking segment is still a drag the medical growth has to overcome to hit the company-wide numbers the price implies. The acquisitions add capability but also integration risk and goodwill, and a serial acquirer in a concentrated customer base is only as good as its discipline on price and integration. The balance sheet is sound, with net debt around 1.3 times operating income, so this is not a solvency concern; it is a question of whether a richly valued, customer-concentrated compounder keeps delivering the growth its price requires, with less margin for a single large customer to disappoint.

Valuation

UFP trades at a clear premium, and the methods we use to triangulate make the structure of that premium visible. The asset-value methods land at roughly a third to a half of the price, and the earnings-power anchor sits well below it, because UFP earns a high return on a small capital base that book-value and zero-growth methods cannot credit. The peer-multiple lens lands closer, modestly below to around the price, valuing UFP against medical-device comparables. Only the growth-cash-flow methods reach the price, which tells you the premium is a bet on continued growth, not anything visible in the static asset or earnings frames.

The concrete statement of what has to be true is the medical-growth durability. The price embeds mid-single-digit-or-better operating growth sustained for years, against a company growing medical sales about 6% and shifting its mix steadily toward that higher-quality revenue. The bet is reasonable given the Intuitive contract extension and the designed-in nature of the components, but it is a premium bet: the price is paying for the growth to persist and for the customer concentration not to bite. The peer comparison is the right lens here, against other medical-device suppliers rather than general packaging, and on that basis UFP is valued as a quality compounder, not a bargain.

Solvency is comfortable and frames the bet as one about growth rather than survival. Net debt of about $118 million sits at roughly 1.3 times trailing operating income, with interest coverage above 10 times, modest leverage for a profitable manufacturer funding acquisitions and capacity expansion. The decisive point for this name is not the balance sheet but the concentration: the price requires the medical franchise and its largest customers to keep compounding, and the contracted visibility through 2029 supports that while also defining exactly where the risk sits.

Catalysts

Q1 2026 was a steady quarter built on the medical mix. Net income rose to $17.5 million, up 1.8%, on net sales of $154.2 million, up 4.1%, with GAAP EPS of $2.24 and adjusted EPS of $2.48. The story underneath was the divergence: medical sales up 5.9% to $143.4 million on strength in robotic surgery, patient surfaces and support, and interventional and surgical, while non-medical fell 15.0% to $10.8 million.

The most important recent development is contractual. In late February 2026 UFP extended and expanded its manufacturing supply agreement with Intuitive Surgical through December 31, 2029, a longer-term, higher-volume partnership that adds visibility to the contracted revenue base. On capacity, the company is adding production in the Dominican Republic in Q2 2026 to support medical growth, and it continues to integrate the 2025 UNIPEC and TPI acquisitions.

The catalysts ahead are the ramp of the expanded Intuitive volumes, the contribution from new Dominican Republic capacity, and the pace of medical growth across the robotic-surgery and surgical segments. The non-medical decline and any new acquisition are secondary watch items. Because the franchise is concentrated, the single most informative future data point is each quarter's medical-segment growth, which is the engine the premium valuation depends on.

Peer Cohorts (Per Segment, With Filing Citations)

UFP Technologies (consolidated) (reported)

• ITGR (INTEGER HOLDINGS CORPORATION)
• FY2025 10-K: …of manufacturing operations. - 91 - Table of Contents INTEGER HOLDINGS CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (12.) RESTRUCTURING AND OTHER CHARGES (Continued) Global Manufacturing Alignment - In 2025, the Company commenced an initiative designed to leverage its global footprint and scale to…
• FY2025 10-K: …financial statements of the Company have been prepared using the asset and liability approach to account for income taxes, which requires the recognition of deferred income taxes for the expected future tax consequences of net operating losses, credits, and temporary differences between the financial statement…
• WST (WEST PHARMACEUTICAL SERVICES, INC.)
• FY2025 10-K: …$47 million in customer incentives received in connection with volumes achieved during 2024 that were not repeated in the same period in 2025. Contract-Manufactured Products - Contract-Manufactured Products gross profit decreased by $2.2 million, or 2.2%, in 2025. Contract-Manufactured Products gross profit margin…
• FY2025 10-K: . We compete with several companies across our major product lines. Because of the special nature of these products, competition is based primarily on product design and performance, although total cost is becoming increasingly important as pharmaceutical companies continue with aggressive cost-control programs across…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.